EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 36 (Octobre 2020) Hors série n° 1 Med Sci (Paris), 36 (2020) 47-49 Références
Accès gratuit
Numéro
Med Sci (Paris)
Volume 36, Octobre 2020
Les jeunes contre le cancer : la Ligue en soutien
Page(s) 47 - 49
DOI https://doi.org/10.1051/medsci/2020196
Publié en ligne 14 octobre 2020
  1. Tang W, Chang SB, Hemler ME. Links between CD147 function, glycosylation, and caveolin-1. Mol Biol Cell 2004 ; 15 : 4043–4050. [CrossRef] [PubMed] [Google Scholar]
  2. Caudroy S, Polette M, Nawrocki-Raby B, et al. EMMPRIN-mediated MMP regulation in tumor and endothelial cells. Clin Exp Metastasis 2002 ; 19 : 697–702. [CrossRef] [PubMed] [Google Scholar]
  3. Kanekura T, Chen X, Kanzaki T. Basigin (cd147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblasts. Int J Cancer 2002 ; 99 : 520–528. [CrossRef] [PubMed] [Google Scholar]
  4. Rucci N, Millimaggi D, Mari M, et al. Receptor activator of NF-kB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147. Cancer Res 2010 ; 70 : 6150–6160. [Google Scholar]
  5. Quemener C, Gabison EE, Naïmi B, et al. Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res 2007 ; 67 : 9–15. [Google Scholar]
  6. Bougatef F, Quemener C, Kellouche S, et al. EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2 -mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood 2009 ; 114 : 5547–5556. [Google Scholar]
  7. Bougatef F, Menashi S, Khayati F, et al. EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2. PLoS One 2010 ; 5 : e12265. [CrossRef] [PubMed] [Google Scholar]
  8. Le Floch R, Chiche J, Marchiq I, et al. CD147 subunit of lactate/H+ symporters MCT1 and hypoxia-inducible MCT4 is critical for energetics and growth of glycolytic tumors. Proc Natl Acad Sci USA 2011 ; 108 : 16663–16668. [CrossRef] [Google Scholar]
  9. Yang H, Zou W, Li Y, et al. Bridge linkage role played by CD98hc of anti-tumor drug resistance and cancer metastasis on cisplatin-resistant ovarian cancer cells. Cancer Biol Ther 2007 ; 6 : 942–947. [CrossRef] [PubMed] [Google Scholar]
  10. Sato M, Nakai Y, Nakata W, et al. EMMPRIN promotes angiogenesis, proliferation, invasion and resistance to sunitinib in renal cell carcinoma, and its level predicts patient outcome. PLoS One 2013 ; 8 : e74313. [CrossRef] [PubMed] [Google Scholar]
  11. Qin Z, Dai L, Bratoeva M, et al. Cooperative roles for emmprin and LYVE-1 in the regulation of chemoresistance for primary effusion lymphoma. Leukemia 2011 ; 25 : 1598–1609. [CrossRef] [PubMed] [Google Scholar]
  12. Baba M, Inoue M, Itoh K, et al. Blocking CD147 induces cell death in cancer cells through impairment of glycolytic energy metabolism. Biochem Biophys Res Commun 2008 ; 374 : 111–116. [Google Scholar]
  13. Fan XY, He D, Sheng CB, et al. Therapeutic anti-CD147 antibody sensitizes cells to chemoradiotherapy via targeting pancreatic cancer stem cells. Am J Transl Res 2019 ; 11 : 3543–3554. [PubMed] [Google Scholar]
  14. Fu Z, Wang L, Cui H, et al. A novel small-molecule compound targeting CD147 inhibits the motility and invasion of hepatocellular carcinoma cells. Oncotarget 2016 ; 7 : 9429–9447. [CrossRef] [PubMed] [Google Scholar]
  15. Spinello I, Saulle E, Quaranta MT, et al. The small-molecule compound AC-73 targeting CD147 inhibits leukemic cell proliferation, induces autophagy and increases the chemotherapeutic sensitivity of acute myeloid leukemia cells. Haematologica 2019 ; 104 : 973–985. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.